Valneva SE Asset Resilience Ratio
Valneva SE asset resilience ratio. Valneva SE (VLA) has an Asset Resilience Ratio of 0.03% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Valneva SE defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Valneva SE (2005–2014)
Asset resilience ratio of Valneva SE from 2005 to 2014. This chart shows how Valneva SE's Asset Resilience Ratio has changed over time. Read Valneva SE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Valneva SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VLA current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €150.00K | 0.03% |
| Total Liquid Assets | €150.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Valneva SE maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Valneva SE Industry Peers by Asset Resilience Ratio
Compare Valneva SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Valneva SE Asset Resilience Ratio by Year (2005–2014)
Valneva SE asset resilience ratio by year from 2005 to 2014. The table below shows the annual Asset Resilience Ratio data for Valneva SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2014-12-31 | 0.01% | €19.00K ≈ $22.21K |
€227.52 Million ≈ $265.99 Million |
-1.43pp |
| 2013-12-31 | 1.44% | €3.66 Million ≈ $4.28 Million |
€254.39 Million ≈ $297.41 Million |
-19.48pp |
| 2012-12-31 | 20.92% | €11.22 Million ≈ $13.12 Million |
€53.67 Million ≈ $62.74 Million |
-7.34pp |
| 2011-12-31 | 28.25% | €20.65 Million ≈ $24.14 Million |
€73.08 Million ≈ $85.44 Million |
+18.50pp |
| 2010-12-31 | 9.75% | €7.75 Million ≈ $9.07 Million |
€79.50 Million ≈ $92.94 Million |
+0.06pp |
| 2008-12-31 | 9.70% | €4.01 Million ≈ $4.69 Million |
€41.38 Million ≈ $48.38 Million |
-19.50pp |
| 2007-12-31 | 29.20% | €11.56 Million ≈ $13.51 Million |
€39.58 Million ≈ $46.28 Million |
+17.93pp |
| 2006-12-31 | 11.27% | €1.68 Million ≈ $1.97 Million |
€14.92 Million ≈ $17.45 Million |
-11.83pp |
| 2005-12-31 | 23.10% | €3.37 Million ≈ $3.94 Million |
€14.60 Million ≈ $17.07 Million |
-- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more